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ABSTRACT
Objective: To explore clinical phenotype and characteristics of Parkinson disease (PD) at different
ages at onset in recently diagnosed patients with untreated PD.
Methods: We have analyzed baseline data from the Parkinson’s Progression Markers Initiative
database. Four hundred twenty-two patients with a diagnosis of PD confirmed by DaTSCAN
imaging were divided into 4 groups according to age at onset (onset younger than 50 years,
50–59 years, 60–69 years, and 70 years or older) and investigated for differences in side, type
and localization of symptoms, occurrence/severity of motor and nonmotor features, nigrostriatal
function, and CSF biomarkers.
Results: Older age at onset was associated with a more severe motor and nonmotor phenotype, a
greater dopaminergic dysfunction on DaTSCAN, and reduction of CSF a-synuclein and total tau.
The most common presentation was the combination of 2 or 3 motor symptoms (bradykinesia,
resting tremor, and rigidity) with rigidity being more common in the young-onset group. In about
80% of the patients with localized onset, the arm was the most affected part of the body, with no
difference across subgroups.
Conclusions: Although the presentation of PD symptoms is similar across age subgroups, the
severity of motor and nonmotor features, the impairment of striatal binding, and the levels of
CSF biomarkers increase with age at onset. The variability of imaging and nonimaging biomarkers
in patients with PD at different ages could hamper the results of future clinical trials. Neurology®
2016;86:1400–1407
GLOSSARY
Ab1–42 5 b-amyloid 1–42; a-syn5 a-synuclein; HC 5 healthy control; HVLT 5 Hopkins Verbal Learning Test; H&Y5 Hoehn
and Yahr; MDS-UPDRS 5 Movement Disorder Society–Unified Parkinson’s Disease Rating Scale; MoCA 5 Montreal Cog-
nitive Assessment; PD 5 Parkinson disease; PPMI 5 Parkinson’s Progression Markers Initiative; p-tau181 5 tau phosphor-
ylated at Thr181; SCOPA-AUT 5 Scales for Outcomes in Parkinson’s Disease–Autonomic; STAI 5 State-Trait Anxiety
Inventory; t-tau 5 total tau; UPSIT 5 University of Pennsylvania Smell Identification Test.
Parkinson disease (PD) is heterogeneous in clinical manifestations1 and progression.2 The bio-
logical basis of this phenotypic variability is unknown but might be explained by the progressive
and diverse accumulation of a-synuclein (a-syn) in different brain structures.3,4 It has been
estimated that PD increases with age, reaching a prevalence of 2.6% in people aged 85 to 89
years.5 Although current evidence does not support the hypothesis that PD is caused by an
acceleration of a natural aging process,6 age is considered its main risk factor.7 Lewy body
pathology is related to age8 and, in the general population, the occurrence of mild extrapyram-
idal signs increases with age.8 These observations implicate a role for age in the progressive
decline of nigrostriatal function.9 However, evidence supporting an influence of age on PD
phenotype at its onset is lacking and conflicting.10–18 Previous studies have poorly assessed the
full spectrum of motor and nonmotor symptoms and they have not evaluated the relationship
between PD phenotype and imaging and nonimaging biomarkers.
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The Parkinson’s Progression Markers Ini-
tiative (PPMI) is an ongoing, international,
multicenter, prospective study designed to dis-
cover and validate biomarkers of disease pro-
gression in newly diagnosed, drug-naive
patients with PD. Here, we have analyzed
baseline data from the PPMI database to
explore the characteristics of patients with
PD at different ages at onset.
METHODS Population. Demographic information, clinical
characteristics, and results of clinical and biochemical tests were
downloaded on August 13, 2014, from the PPMI database.19
Inclusion criteria were age 30 years or older, diagnosis of PD
(based on one of the following: presence of [1] asymmetrical
resting tremor or [2] asymmetrical bradykinesia or [3] at least 2
of resting tremor, bradykinesia, and rigidity), disease duration of
1 to 24 months, Hoehn and Yahr (H&Y) stage of 1 to 2, and
presence of striatal dopamine transporter deficit on 123I-ioflupane
SPECT imaging (DaTSCAN).
None of the patients was on antiparkinsonian medications or
monoamine oxidase inhibitor inhibitors.
At enrollment, participants were assessed for clinical features
and underwent DaTSCAN imaging. CSF and serum samples
were collected. Healthy controls (HCs) were recruited if free of
current or active neurologic disorder and had normal DaTSCAN.
Details about assessments and analyses are described in the
e-Methods on the Neurology® Web site at Neurology.org.
Our PD population was divided into subgroups according to
the decade of their age at symptomatic onset (younger than 50
years, 50–59 years, 60–69 years, and 70 years or older). Age-
related differences in clinical phenotype and imaging and
nonimaging biomarkers were evaluated. This age-subgroup clas-
sification was chosen following a cluster analysis of patients with
early PD.20 Age at onset was based on patients’ recollection of first
symptoms.
Standard protocol approvals, registrations, and patient
consents. The PPMI study is registered with ClinicalTrials.gov
(NCT01141023). Each PPMI site received approval from an
ethical committee on human experimentation before study initi-
ation. Written informed consent for research was obtained from
all individuals participating in the study.
Statistical analysis. Continuous variables were expressed as
mean 6 SD and compared across subgroups with analysis of var-
iance if normally distributed and with the Kruskal-Wallis correction
when not normally distributed. Normality of data distribution was
interrogated using the Kolmogorov-Smirnov test. Significance of
multiple comparisons was assessed after performing a Bonferroni
correction. Categorical variables were expressed as proportions and
compared using a x2 test. Correlations were interrogated using
Spearman rank correlation. Data were collected and analyzed
using SPSS version 19.0 (IBM Corp., Armonk, NY). Statistical
significance was accepted at p , 0.05.
RESULTS Patient characteristics. Table 1 shows
demographic and clinical characteristics of the PD pop-
ulation. We studied 422 patients with PD, 276 male
(65.4%), with a mean age of 61.6 6 9.7 years and
mean years of education of 15.56 3.0. Three hundred
seventy-five patients (88.8%) were right-handed,
Table 1 Characteristics of all patients with PD and at different ages at onset
All (n 5 422)
Age at onset, y
p Value<50 (n 5 58) 50–59 (n 5 117) 60–69 (n 5 168) ‡70 (n 5 79)
Age, y, mean 6 SD 61.6 6 9.73 45.03 6 4.97 55.74 6 2.92 65.46 6 2.99 74.25 6 3.3 —
Sex, male, % (n) 65.4 (276) 63.8 (37) 55.6 (65) 71.4 (120) 68.4 (54) —
PD duration, mo, mean 6 SD 6.58 6 6.51 6.78 6 7.15 6.49 6 6.59 6.43 6 6.09 6.86 6 6.88 1.000
H&Y stage, mean 6 SD 1.56 6 0.51 1.40 6 0.49 1.49 6 0.52 1.61 6 0.50a 1.70 6 0.46a,b 0.001
Family history of PD, % (n) 24.2 (102) 25.9 (15) 26.5 (31) 22.0 (37) 24.1 (19) 0.835
Years of education, mean 6 SD 15.54 6 2.99 15.79 6 2.62 15.28 6 2.62 15.49 6 3.10 15.84 6 3.50 0.413
Motor subtype, % (n) 0.533
Tremor-dominant 17.8 (75) 20.7 (12) 14.5 (17) 16.1 (27) 24.1 (19)
Akinetic-dominant 78 (329) 75.9 (44) 81.2 (95) 80.4 (135) 69.6 (55)
Mixed 4.3 (18) 3.4 (2) 4.3 (5) 3.6 (6) 6.3 (5)
MDS-UPDRS, mean 6 SD
Part I 5.57 6 4.07 5.21 6 4.12 5.38 6 3.72 5.68 6 4.48 5.86 6 3.60 0.516
Part II 5.90 6 4.20 6.09 6 5.03 5.20 6 3.52 6.04 6 4.32 6.53 6 4.10 0.181
Part III in OFF 20.89 6 8.87 18.09 6 7.97 19.80 6 8.47 21.49 6 8.81a 23.30 6 9.55a 0.005
Total 32.35 6 13.15 28.38 6 14.16 30.38 6 11.44 33.21 6 13.73 35.64 6 12.81a 0.009
Abbreviations: H&Y 5 Hoehn and Yahr; MDS-UPDRS 5 Movement Disorder Society–Unified Parkinson’s Disease Rating Scale; PD 5 Parkinson disease.
Bonferroni analysis performed.
ap Value , 0.05 vs age at onset ,50 years.
bp Value , 0.05 vs age at onset 50–59 years.
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76 patients (8.8%) were left-handed, and 10 patients
(2.4%) were ambidextrous. One hundred two
patients (24.2%) had a family history of PD. Mean
PD duration was 6.6 6 6.5 months. Mean H&Y
stage was 1.56 6 0.51 and Movement Disorder
Society–Unified Parkinson’s Disease Rating Scale
(MDS-UPDRS) total mean score was 32.4 6 13.2.
Fifty-eight patients had age at onset younger than 50
years, 117 had age at onset between 50 and 59 years,
168 between 60 and 69 years, and 79 had age at onset
of 70 years or older. There were no differences for
years of education, family history of PD, and PD
duration. Table e-1 shows characteristics of the
control population.
Side predominantly affected at onset. Disease onset was
asymmetrical in 403 patients (97.8%) and symmetri-
cal in 9 (2.2%). In patients with asymmetrical onset,
234 (56.8%) had the dominant side predominantly
affected and 169 (41%) the nondominant side. In
subgroups with older age at onset, the number of
patients with the dominant side more affected and
symmetrical onset was higher compared to younger
subgroups (p 5 0.002) (table 2).
Localization of motor symptoms. MDS-UPDRS III
subitems were analyzed to identify involvement of
specific parts of the body. In 191 patients (45.3%),
the disease predominantly affected a specific part of
the body (head-predominant, arm-predominant, or
leg-predominant; see e-Methods for details about
this classification). Of these patients, 162 (85%)
had arm-predominant symptoms, 15 (8%) had
head-predominant symptoms, and 14 (7.3%) had
leg-predominant symptoms. Most patients had arm-
predominant symptoms (80%–86%) (table 2).
Symptoms at time of diagnosis. Fifty-two patients
(12.4%) reported only one motor symptom (resting
tremor [40 patients, 76.9%], bradykinesia [10
patients, 19.2%], or rigidity [2 patients, 3.8%]),
151 (35.9%) reported 2 motor symptoms, 200
(47.5%) reported 3 motor symptoms, and 18
(4.3%) reported all 4 motor symptoms of PD
(table 3). Overall the percentage of patients with
1, 2, 3, and 4 motor symptoms at time of diagnosis
was similar across age subgroups (p 5 0.5). In the
subgroup with age at onset younger than 50 years,
94.5% (n5 54) of the patients reported rigidity and
this rate was higher compared to other age-at-onset
subgroups (p 5 0.003). The percentages of patients
reporting bradykinesia, resting tremor, and postural
instability rate were similar at different ages at onset
(p5 0.626, p5 0.130, and p5 0.839, respectively)
(table 3).
Motor features. Table 1 shows details of motor fea-
tures. The mean H&Y stage for the whole cohort of
patients was 1.56 6 0.51. They had an MDS-
UPDRS Part II mean score of 5.9 6 4.20 and an
MDS-UPDRS Part III motor mean score of 20.9 6
8.9. Seventy-five patients (17.8%) showed a
tremor-dominant subtype, 329 (78%) an akinetic-
rigid subtype, and 18 (4.3%) a mixed subtype.
Details regarding definition of motor subtypes are
provided in the e-Methods. MDS-UPDRS subscore
for bradykinesia was 10.41 6 5.68 (range 0–52),
3.79 6 2.65 for rigidity (range 0–20), 2.79 6 2.42
for resting tremor (range 0–24), and 0.68 6 0.73
for postural instability (range 0–12) (table 3).
H&Y stage and MDS-UPDRS III score was higher
in the subgroups with older age at onset (p 5 0.001
and p 5 0.005, respectively). However, no differen-
ces were found for MDS-UPDRS Part II and motor
subtypes (p 5 0.181 and p 5 0.533, respectively)
(table 1). Bradykinesia, resting tremor, and postural
instability scores were more severe in the subgroup
with older age at onset than in the younger subgroups
(p5 0.040, p5 0.004, and p5 0.039, respectively),
Table 2 Predominantly affected side and localization of motor symptoms in all patients with Parkinson
disease and at different ages at onset
All
Age at onset, y
p Value<50 50–59 60–69 ‡70
Predominantly affected side n 5 412 n 5 57 n 5 113 n 5 164 n 5 78
Nondominant side 41 (169) 54.4 (31) 45.1 (51) 36.6 (60) 34.6 (27) 0.002
Dominant side 56.8 (234) 45.6 (26) 54.9 (62) 61.6 (101) 57.7 (45)
Symmetrical involvement 2.2 (9) 0 (0) 0 (0) 1.8 (3) 7.7 (6)
Localization of motor symptoms n 5 191 n 5 30 n 5 52 n 5 74 n 5 35
Head-predominant 7.9 (15) 0 (0) 3.8 (2) 9.5 (7) 17.1 (6) 0.530
Arm-predominant 84.8 (162) 86.7 (26) 84.6 (44) 86.5 (64) 80 (28)
Leg-predominant 7.3 (14) 13.3 (4) 11.5 (6) 4.1 (3) 2.9 (1)
Data represent % (n).
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whereas severity of rigidity was not different across
age subgroups (p 5 0.962) (table 3).
Nonmotor features. Table 4 shows details of nonmotor
symptoms analysis. The global nonmotor burden as
measured by the MDS-UPDRS Part I was similar
among the 4 subgroups (p 5 0.516) (table 1).
However, when rated with specific scales, patients
with an older age at onset showed a greater
impairment of autonomic (Scales for Outcomes in
Parkinson’s Disease–Autonomic [SCOPA-AUT],
p , 0.0001), olfactory (University of Pennsylvania
Smell Identification Test [UPSIT], p, 0.0001), and
cognitive function (Montreal Cognitive Assessment
[MoCA], p , 0.0001; Benton Judgment of Line
Orientation Score, p 5 0.018; Hopkins Verbal
Learning Test [HVLT] Delayed Recognition False
Alarms, p 5 0.032; HVLT Delayed Recognition
Hits, p 5 0.001; HVLT Immediate Recall, p ,
0.0001; Semantic Fluency Test score, p , 0.0001;
Symbol Digit Modalities Test score, p , 0.0001).
Likewise, the number of patients with impaired
autonomic, olfactory, and cognitive functions was
higher in the subgroups with older age at onset
(p , 0.0001, for SCOPA-AUT, p , 0.0001 for
UPSIT, and p , 0.0001 for MoCA, respectively;
data not shown). No differences were found in
terms of severity of disability (activities of daily
living, p 5 0.489), depression (Geriatric Depression
Scale, p 5 0.890), anxiety (State-Trait Anxiety
Inventory [STAI] total, p 5 0.639; STAI state
subscore, p 5 0.948; STAI anxiety subscore, p 5
0.486), impulsive control disorders (Questionnaire
for Impulsive-Compulsive Disorders in Parkinson’s
Disease score, p 5 0.673), and sleep problems
(Epworth Sleepiness Scale, p 5 0.980; REM Sleep
Behavior Disorder Screening Questionnaire, p 5
0.941).
Striatal binding of 123I-ioflupane (DaTSCAN). Table 5
shows DaTSCAN findings. Data are presented as
reduction in 123I-ioflupane binding compared to the
mean of the HCs (see details in e-Methods). In all
patients, striatal uptake of 123I-ioflupane was asym-
metrical with one side more affected than the other.
In each patient, we identify the caudate and putamen
with the largest reduction of 123I-ioflupane binding
(referred to below as the most affected caudate and
most affected putamen). The contralateral striatal
nuclei were defined as the least affected caudate and
putamen. Each nucleus was considered abnormally
reduced when reduction was greater than 2 SDs
below mean value of HCs for that region. Across
the whole population of patients, the mean percent-
age reduction in 123I-ioflupane binding was 68.5%6
12.4% for the most affected putamen, 53.8% 6
17.4% for the least affected putamen, 39% 6 18.2%
for the most affected caudate, and 26.6%6 20.1% for
the least affected caudate. Three hundred ninety pa-
tients had an abnormal most affected putamen
Table 3 Number, rate, and severity of motor signs at different ages at onset
All
Age at onset, y
p Value<50 50–59 60–69 ‡70
No. of motor signs n 5 421 n 5 58 n 5 117 n 5 168 n 5 78
1 12.4 (52) 3.4 (2) 13.7 (16) 12.5 (21) 16.7 (13) 0.500
2 35.9 (151) 36.2 (21) 36.8 (43) 35.7 (60) 34.6 (27)
3 47.5 (200) 58.6 (34) 44.4 (52) 47.6 (80) 43.6 (34)
4 4.3 (18) 1.7 (1) 5.1 (6) 4.2 (7) 5.1 (4)
Rate of motor signs n 5 422 n 5 58 n 5 117 n 5 168 n 5 79
Bradykinesia 82.2 (347) 86.2 (50) 84.5 (98) 82.5 (137) 78.5 (62) 0.626
Rigidity 75.8 (320) 94.8 (55) 76.1 (89)a 73.1 (122)a 70.1 (54)a 0.003
Tremor 78.2 (330) 72.4 (42) 72.6 (85) 82.7 (139) 81.0 (64) 0.130
Postural instability 6.9 (29) 5.4 (3) 8.7 (10) 6.6 (11) 6.3 (5) 0.839
Severity of motor signs, MDS-UPDRS subscore n 5 422 n 5 58 n 5 117 n 5 168 n 5 79
Bradykinesia (0–52) 10.41 6 5.68 8.91 6 5.06 10.00 6 5.35 10.66 6 5.64 11.57 6 6.42a 0.040
Rigidity (0–20) 3.79 6 2.65 3.76 6 2.64 3.77 6 2.67 3.87 6 2.65 3.68 6 2.67 0.962
Resting tremor (0–24) 2.79 6 2.42 2.21 6 2.40 2.26 6 2.16 2.95 6 2.50 3.66 6 2.35a,b 0.004
Postural instability (0–12) 0.68 6 0.73 0.45 6 0.63 0.66 6 0.76 0.73 6 0.75 0.78 6 0.67a 0.039
Data represent % (n) or mean 6 SD. Bonferroni analysis performed.
ap Value , 0.05 vs age at onset ,50 years.
bp Value , 0.05 vs age at onset 50–59 years.
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(93.5%), 262 patients an abnormal least affected puta-
men (62.5%), 197 patients had an abnormal most
affected caudate (47%), and 93 patients had an abnor-
mal least affected caudate (22.2%) (table 5). Percentage
reductions in 123I-ioflupane binding for the most
affected putamen were similar across age subgroups
(p5 0.926) as were the number of patients with abnor-
mal reductions (p 5 0.123). For the most affected
caudate, 123I-ioflupane binding was lower in older age
subgroups (p 5 0.048); however, the number of pa-
tients with abnormal caudate reduction was similar
across the age subgroups (p 5 0.229). In the least
affected putamen and caudate, 123I-ioflupane binding
was lower in older compared with younger subgroups
(p 5 0.006 for putamen and p 5 0.0003 for caudate)
and the number of patients with abnormal tracer
uptake in these regions was higher in older subgroups
(p 5 0.004 for putamen and p 5 0.047 for caudate)
(table 5).
CSF and serum biomarkers. Table e-2 shows character-
istics of CSF and serum biomarkers. Across the whole
population, the levels of CSF a-syn, total tau (t-tau),
and tau phosphorylated at Thr181 (p-tau181) were
reduced in the patients compared with HCs, while
levels of CSF b-amyloid 1–42 (Ab1–42) and serum
urate were not different between groups (table e-2).
In HCs, all biomarkers increased with the age (Spear-
man correlation [r] 5 0.159, p 5 0.029 for a-syn;
r5 0.354, p5 0.030 for t-tau; r5 0.158, p5 0.030
Table 4 Nonmotor features at different ages at onset
All (n 5 422)
Age at onset, y
p Value<50 (n 5 58) 50–59 (n 5 117) 60–69 (n 5 168) ‡70 (n 5 79)
Autonomic dysfunction
SCOPA-AUT 9.49 6 6.16 6.98 6 5.24 8.77 6 5.58 10.13 6 6.31a 11.05 6 6.67a ,0.0001
Neurobehavioral impairments
GDS 2.34 6 2.45 2.66 6 2.78 2.38 6 2.61 2.29 6 2.46 2.13 6 1.88 0.890
QUIP score 0.28 6 0.63 0.31 6 0.57 0.26 6 0.65 0.65 6 0.28 0.67 6 0.28 0.673
STAI total score 88.16 6 8.81 87.47 6 8.64 88.03 6 9.19 88.16 6 9.12 88.90 6 7.71 0.639
STAI state subscore 42.76 6 4.92 42.40 6 5.31 42.38 6 5.23 42.91 6 5.07 42.81 6 3.70 0.948
STAI anxiety subscore 45.41 6 5.24 45.07 6 5.22 45.34 6 5.56 45.21 6 5.14 46.19 6 4.96 0.486
Neuropsychological impairments
MoCA 27.29 6 2.31 28.19 6 2.40 27.52 6 2.05 27.04 6 2.24a 26.81 6 2.56a ,0.0001
BJLOS 12.78 6 2.12 13.22 6 1.86 12.94 6 1.90 12.82 6 2.21 12.13 6 2.32a 0.018
HVLT Delayed Recognition False Alarms 1.24 6 1.32 0.97 6 1.17 1.13 6 1.23 1.46 6 1.43 1.13 6 1.23 0.032
HVLT Delayed Recognition Hits 11.18 6 1.23 11.52 6 0.73 11.47 6 0.78 11.01 6 1.40a,b 10.86 6 1.52b 0.001
HVLT Immediate Recall 24.44 6 4.98 27.12 6 3.80 25.78 6 4.75 23.21 6 4.74a,b 23.13 6 5.37a,b ,0.0001
SFT score 48.68 6 11.64 52.19 6 10.49 53.09 6 11.49 46.52 6 11.26a,b 44.24 6 10.75a,b ,0.0001
SDMT score 41.20 6 9.73 48.81 6 8.18 44.05 6 8.13a 39.68 6 9.13a,b 34.66 6 9.01a,b,c ,0.0001
LNSR score 14.46 6 2.04 15.36 6 1.80 14.68 6 2.14 13.62 6 2.02 13.80 6 1.64 0.162
Olfactory dysfunction
UPSIT 22.36 6 8.24 26.33 6 7.44 24.44 6 8.03 21.28 6 7.95a,b 18.68 6 7.77a,b ,0.0001
Sleep problems
ESS 5.76 6 3.42 5.60 6 3.32 5.68 6 3.35 5.88 6 3.64 5.74 6 3.13 0.980
RBDSQ 4.5 6 2.87 4.48 6 2.72 4.46 6 2.96 4.60 6 2.89 4.35 6 2.85 0.941
Disability
Modified Schwab and England ADL 93.15 6 5.87 92.59 6 5.56 93.59 6 5.87 92.83 6 6.13 93.58 6 5.55 0.489
Abbreviations: ADL 5 activities of daily living; BJLOS 5 Benton Judgment of Line Orientation Score; ESS 5 Epworth Sleepiness Scale; GDS 5 Geriatric
Depression Scale; HVLT 5 Hopkins Verbal Learning Test; LNSR 5 Letter Number Sequencing Raw; MoCA 5 Montreal Cognitive Assessment; QUIP 5
Questionnaire for Impulsive-Compulsive Disorders in Parkinson’s Disease; RBDSQ 5 REM Sleep Behavior Disorder Screening Questionnaire; SCOPA-AUT 5
Scales for Outcomes in Parkinson’s Disease–Autonomic; SDMT 5 Symbol Digit Modalities Test; SFT 5 Semantic Fluency Test; STAI 5 State-Trait Anxiety
Inventory; UPSIT 5 University of Pennsylvania Smell Identification Test.
Data represent mean 6 SD. Bonferroni analysis performed.
ap Value , 0.05 vs age at onset ,50 years.
bp Value , 0.05 vs age at onset 50–59 years.
cp Value , 0.05 vs age at onset 60–69 years.
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for p-tau181; and r 5 0.182, p 5 0.008 for serum
urate) except for Ab1–42 (r520.012, p5 0.871). In
patients with PD, only a-syn (r 5 0.124, p5 0.012)
and t-tau (r 5 0.269, p, 0.0001) increased with the
age but not p-tau181 (r 5 0.054, p 5 0.277), Ab1–42
(r 5 0.159, p 5 0.029), or serum urate (r 5 0.068,
p 5 0.166). In older age subgroups, the reduction
(from HCs) of a-syn and t-tau were greater compared
with younger age subgroups (table e-2 and figure e-1).
DISCUSSION The main strength of this study is that
the clinical features of PD were evaluated in a large
population of untreated newly diagnosed patients
with a prospective design and a simultaneous evalua-
tion of imaging and nonimaging biomarkers.
We found that older age at onset was associated
with a more severe motor and nonmotor PD pheno-
type, a greater impairment of dopaminergic function
on DaTSCAN, and a greater reduction of CSF a-syn
and t-tau levels. With the exception of rigidity, which
was similar across age groups, the severity of motor
impairment (H&Y stage, MDS-UPDRS total and
Part III scores, bradykinesia, resting tremor, and pos-
tural instability scores) was greater in the oldest age
subgroup (70 years or older) compared with younger
subgroups. In addition, the number of patients with
symmetrical disease at onset was higher in the oldest
(70 years or older) compared with younger age sub-
groups suggesting a more widespread degeneration.
Similarly, the oldest age subgroups also presented more
severe nonmotor symptoms (autonomic, olfactory, and
cognitive dysfunctions) and greater reduction of striatal
123I-ioflupane binding on DaTSCAN compared with
younger subgroups. Of note, while 123I-ioflupane
uptake in the most affected putamen was similar across
the age subgroups, uptake in the most affected caudate,
least affected putamen, and least affected caudate was
lower in older compared with younger subgroups,
suggesting a more widespread involvement of striatal
structures in elderly patients.
Finally, levels of CSF a-syn and t-tau were
reduced in patients with PD, as previously suggested
in the preliminary analysis of the PPMI population,21
and this reduction was greater in older age subgroups
compared with younger age subgroups. A greater
reduction in CSF a-syn and t-tau in patients with
older onset could be explained by a higher accumu-
lation of these proteins in the neurons.
Considering that these patients had similar disease
duration, our findings of a more severe phenotype
and more widespread involvement of striatal struc-
tures in the older patients could be attributable to
superimposition of PD pathology on the natural
aging process. A direct contribution of the aging pro-
cess to the progressive neurodegeneration of PD or a
decrease of compensatory mechanisms in older pa-
tients could also have occurred.
Moreover, our data suggest that the heterogeneity
of PD at different ages at onset could be reflected by
various impairments of imaging and nonimaging bio-
markers. This variability in biomarkers in patients
with PD with different ages at onset should be taken
in account in future clinical trials to test neuroprotec-
tive drugs. The recruitment of patients with homoge-
neous age at onset will reduce this variability,
resulting in an increased statistical power with smaller
sample sizes. Follow-up observations of the PPMI
population will clarify the role of age at onset on dis-
ease progression and whether there is an interaction
with these biomarkers.
Recently, there has been a great effort to identify and
formally delineate PD subtypes.22,23 So far, none of the
proposed subtype classifications appears sufficiently
robust to warrant formal delineation.22 Our findings
suggest that in future classifications, early-onset and
late-onset subtypes should also be considered.
Table 5 DaTSCAN at different ages at onset
All (n 5 422)
Age at onset, y
p Value<50 (n 5 58) 50–59 (n 5 117) 60–69 (n 5 168) ‡70 (n 5 79)
% Reduction most affected putamen 68.5 6 12.4 68.7 6 9.3 69.1 6 10.7 68.3 6 14.1 68 6 12.8 0.926
% Reduction least affected putamen 53.8 6 17.4 47.1 6 17.8 53.6 6 17.1 54.4 6 18.4a 57.6 6 14.2a 0.006
% Reduction most affected caudate 39 6 18.2 33.4 6 19.9 38.1 6 16.3 40.3 6 18.6 41.5 6 18.3a 0.048
% Reduction least affected caudate 26.6 6 20.1 17.2 6 20.8 25.5 6 19.1 28.6 6 20.3a 31 6 18.5a 0.0003
Patients with abnormal DaTSCAN, % (n)
Abnormal most affected putamen 93.1 (390) 98.2 (56) 94.9 (111) 92.2 (154) 88.5 (69) 0.123
Abnormal least affected putamen 62.5 (262) 42.1 (24) 62.4 (73) 65.9 (110)a 70.5 (55)a 0.004
Abnormal most affected caudate 47 (197) 35.1 (20) 46.2 (54) 49.7 (83) 51.3 (40) 0.229
Abnormal least affected caudate 22.2 (93) 10.5 (6) 18.8 (22) 26.3 (44) 26.9 (21)a 0.047
aBonferroni analysis: p value , 0.05 vs age at onset ,50 years.
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The association between handedness and first
affected side at onset in PD is still controversial, as some
studies have reported an association and others failed to
demonstrate it.24 A recent meta-analysis24 including
4,405 patients with asymmetrical PD has shown that
in about 60% of patients, the disease started on the
dominant side. This finding is confirmed in the overall
population of our study, where the disease was mostly
asymmetrical and the dominant side was predomi-
nantly affected. However, in the youngest subgroup
(younger than 50 years), it was the nondominant side
that was mostly affected. It has been suggested that
increased movement complexity in the dominant hand
could be a risk factor for dopamine cell loss in the
contralateral hemisphere via glutaminergic excitotoxic-
ity.24 Therefore, the dominant hemisphere could be
more vulnerable to dopaminergic denervation than
the nondominant hemisphere in patients with PD.25
However, this theory does not explain the onset in
the nondominant side in our younger patients and
the symmetrical involvement in some of our older pa-
tients. Further studies are required to understand the
pathophysiologic mechanisms of asymmetry in PD.
The limited data available in the literature indicate
that abnormalities of the arm are first noticed in the
majority (65%–80%) of patients.26,27 Similarly, in
about 80% of our patients with localized onset, the
arm was the most affected part of the body, with no
difference across age subgroups. This is in line with
our recent [18F]-dopa PET study,28 which has shown
that the middle strip (intermediate) of the putamen
was more affected than other striatal subregions in
patients with early PD and correlated with severity
of arm impairment.
Regarding the motor picture at onset, we did not
find any specific feature of PD that was typical of any
age subgroup, with the exception of rigidity, which
was more commonly noticed by the group with youn-
gest age at onset, as also reported previously.17,18 Most
patients had a combination of 2 or more motor symp-
toms and we found a similar rate of tremor-predominant
and akinetic-rigid patients across age-at-onset subgroups,
as also indicated previously.12
There are some potential limitations in this study
that require further discussion. In older patients, the
initial symptoms could have been detected later than
in younger patients since these symptoms could be
attributed to physiologic aging rather than to a path-
ologic process. Thus, the disease duration in older pa-
tients could be underestimated in comparison with
younger patients. However, it should be noticed that
the magnitude of tracer uptake in the most affected
putamen on DaTSCAN was similar across the age
subgroups, suggesting that disease duration was
indeed similar in the different subgroups.
Older people have a larger number of comorbidities
and medications than younger patients, which might
lead to higher scores on clinical scales, particularly for
nonmotor symptoms. This is alleviated by the fact that
comparison was made with HCs rigorously age- and
sex-matched to the PD cohort. Unfortunately, the PPMI
study has not included any measure of comorbidities to
be used as covariate in comparisons of age subgroups.
We strongly suggest that measurements of comorbidities
such as the Elixhauser Index or the Romano adaptation
of the Charlson Index be added to the PPMI study and
to similar database studies in the future.29
Finally, about 25% of our patients had a family his-
tory of PD and it is possible that some of them were
carriers of a genetic mutation. Many genetic forms have
an influence on PD phenotype and therefore the pres-
ence of patients with genetic forms of PD could be a
possible confounding factor in our study. However, this
concern is probably mitigated by the equal distribution
of family history across all age groups. In addition,
genetic forms of PD associated with more severe pheno-
types (including more severe and symmetrical striatal
loss of dopamine transporter on DaTSCAN) have early
onset, affecting young patients; therefore, the possible
presence of such patients in our cohort would not
change the meaningfulness of our findings.
Comment:
Biomarkers for the progression of Parkinson disease
The chief outlay for a study of the progression of Parkinson disease (PD) is
time, and many of the important scientific returns from the Parkinson’s Progres-
sion Markers Initiative database lie in the future. Pagano et al.1 have conducted a
cross-sectional survey of the de novo PD patient cohort. One of their conclusions is
that older patients have greater motor and nonmotor deficits with more wide-
spread striatal dopaminergic lesions on DaTSCAN, implying that longitudinal
data should tell us more about the ways that a-synuclein and other pathologies
in PD are governed by age.
The task of correlating clinical scale statistics with prospective biomarkers is
not straightforward. PD may not be divisible into subtypes beyond general trends
of tremor or bradykinesia predominance, and temporal differences between
younger and older onset. “Nonmotor symptoms” is useful shorthand for a group
of parkinsonian disabilities, but there is no common correspondence with disease
stage or pathologic findings among them.
Comparing untreated parkinsonian motor disability with the baseline candi-
date biomarker testing is potentially valuable. Henceforth, though, clinical obser-
vations on this cohort will record motor function that has been modified by
pharmacologic therapy. One motivation for the search for biomarkers of PD
progression was the unsatisfactory outcome of several clinical trials that had been
designed to look for disease-modifying effects. Motor scores could not reliably
discern the rate of disease progression from variations in symptomatic treatment.
Future assessments should account for the responses to dopaminergic drugs so that
the trajectory of the underlying motor progression, which runs at around 2% of
the maximum score per year, can be accurately calculated. Otherwise, the same
blurring of interpretation of motor scores that hindered previous drug trials will
reduce the precision of the correlations with clinical course that are needed to
validate the biomarkers.
1. Pagano G, Ferrara N, Brooks DJ, Pavese N. Age at onset and parkinson disease
phenotype. Neurology 2016;86:1400–1407.
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